The 8th CAR-TCR Summit Europe: Your European Hub of Next Generation Cell Therapy Innovation
Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources. This, along with the recent investments in Enara Bio, ArsenalBio, Kyverna and Artiva signifies that the field is poised to regain momentum.
It’s not just investments that are gaining traction. Recent approvals are changing the game, with Iovance and Adaptimmune making strides in treating solid tumours, Kite securing first-line treatment approval, and donor cell therapies demonstrating success in putting autoimmune diseases into remission. The industry is brimming with new hope!
The 8th CAR-TCR Summit Europe returns to London this February as your must-attend forum to remain on the pulse of recent innovation in cell therapy. Join us to collaborate, innovate, and overcome the shared challenges of safety concerns, high cost of goods, effective tumour targeting and more. Let’s work together to drive success in clinical trials, secure regulatory approvals, and position cell therapy as the first-line treatment for oncological and non-oncological indications.
What's New for 2025?
Autoimmune Focus Day: Your one-stop-shop to explore the latest advancements in cell therapy for autoimmune indications. Dive into key topics including selecting the right indications to target, navigating safety concerns, and more
Regulatory Focus Day: Gain in-depth insights into regulatory strategies, including how to effectively engage with regulators to meet their requirements, and streamline the process. If you’re facing challenges with IND or BLA, this is a must-attend session to sharpen your approach
Refreshed Content Tracks: Spanning Discovery, Clinical Development, and CMC, Process and Analytics to cover the entire breadth of cell therapy development; ensuring hyper-relevant content for your entire team
Top Speakers
"It will be great to re-connect with the community and to see advances on the different avenues of CAR/TCR based therapy"
Zelluna Immunotherapy, 2025 Speaker
Brand New Presenting Companies for 2025
"I’m looking forward to engaging with investors and partners to accelerate our path to IND and approval"
NKILT Therapeutics, Inc. 2025 Speaker